Black Diamond Therapeutics, Inc. (BDTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Black Diamond Therapeutics, Inc.
Address
One Main Street
Cambridge, MA 02142
United States of America (the)
Phone
617 252 0848
Sector
Healthcare
Industry
Biotechnology
Employees
24
First IPO Date
January 31, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Mark A. Velleca | Chief Executive Officer, President & Chairman | 1.04M | 1964 |
| Elizabeth Buck | Co-Founder & Chief Scientific Officer | 340,473 | 1975 |
| Brent Hatzis-Schoch | Chief Operating Officer & General Counsel | 741,216 | 1965 |
| Sergey Yurasov | Chief Medical Officer | 760,748 | 1969 |
| Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller | 0 | 1985 |
| Melanie Morrison | Chief Development Officer | 0 | 1975 |
Description
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
